Eloxx Pharmaceuticals Financial Results
Eloxx Pharmaceuticals reported Q3 2026 financial results and provided a business update on its rare kidney disease pipeline, including the dosing of the first two patients in the Phase 2b EXACT study for Alport syndrome. The company also received FDA IND clearance for its Phase 2 EXPRESS study in ADPKD and ended the quarter with $56.3 million in cash.
- Term
- Q3 2026
“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease.”
Sumit Aggarwal, President and Chief Executive Officer